Alexza's Adasuve FDA approval has several post approval requirements Alexza has several post-approval requirements, including a large observational clinical trial designed to gather patient safety data based on the real-world use of Adasuve, as well as a clinical program addressing the safety and efficacy of Adasuve in agitated adolescent patients.
News For ALXA From The Last 14 Days
Check below for free stories on ALXA the last two weeks.
Alexza Pharmaceuticals announces U.S. commercial launch of Adusave by Teva Alexza Pharmaceuticals (ALXA) announced the U.S. commercial launch of ADASUVE inhalation powder 10mg by its commercial partner, Teva Pharmaceutical Industries (TEVA). ADASUVE is the first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.